insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.

1/5 보강
International journal of hematology 📖 저널 OA 28.8% 2025: 5/14 OA 2026: 16/59 OA 2025~2026 2026 Vol.123(1) p. 41-51
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
178 patients with DLBCL at high risk of CNS relapse who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) or its derivatives with (N = 60) or without (N = 118) CNS prophylaxis.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This advantage was maintained in the multivariate analysis (hazard ratio: 0.160; 95% confidence interval: 0.039-0.663; p = 0.012). [CONCLUSIONS] CNS prophylaxis with HD-MTX + IT improved the prognosis of patients with DLBCL at high risk of CNS relapse.

Miyazawa Y, Yokohama A, Ishizaki T, Saitoh T, Saito A, Toyama K

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[OBJECTIVE] Central nervous system (CNS) prophylaxis is recommended for patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk of CNS relapse.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 60
  • p-value p = 0.013
  • p-value p = 0.012
  • 추적기간 72.8 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Miyazawa Y, Yokohama A, et al. (2026). CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.. International journal of hematology, 123(1), 41-51. https://doi.org/10.1007/s12185-025-04055-4
MLA Miyazawa Y, et al.. "CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.." International journal of hematology, vol. 123, no. 1, 2026, pp. 41-51.
PMID 40859046 ↗
DOI 10.1007/s12185-025-04055-4

Abstract

[OBJECTIVE] Central nervous system (CNS) prophylaxis is recommended for patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk of CNS relapse. This study aimed to determine the impact of CNS prophylaxis on CNS relapse rates and overall survival (OS) in this patient population, as well as the optimal method for CNS prophylaxis.

[METHODS] This was a retrospective analysis of 178 patients with DLBCL at high risk of CNS relapse who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) or its derivatives with (N = 60) or without (N = 118) CNS prophylaxis.

[RESULTS] The 2-year CNS relapse rate was 17.6% in the all-prophylaxis group (HD-MTX 17.4%, IT 48.1%, and HD-MTX + IT 6.2%) and 13.0% in the non-prophylaxis group, with no significant difference between groups. However, HD-MTX + IT decreased the risk of CNS relapse. After a median follow-up of 72.8 months, HD-MTX + IT addition significantly improved the 5-year OS (HD-MTX 73.5%, IT 44.4%, HD-MTX + IT 93.2%; non-prophylaxis group 58.0%; p = 0.013). This advantage was maintained in the multivariate analysis (hazard ratio: 0.160; 95% confidence interval: 0.039-0.663; p = 0.012).

[CONCLUSIONS] CNS prophylaxis with HD-MTX + IT improved the prognosis of patients with DLBCL at high risk of CNS relapse.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 3개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반